NCT02406443View on ClinicalTrials.gov

The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

January 31, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

Sitaglitpin

Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days

OTHER

Placebo

Oral tablet (no medicinal ingredients) administered once daily for 28 days

Trial Locations (1)

M5G 2N2

University Health Network - Division of Nephrology, Toronto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT02406443 - The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion | Biotech Hunter | Biotech Hunter